REG - Trellus Health PLC - Two contracts signed with Mount Sinai

Trellus HealthAnnouncement

17/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221017:nRSQ0108Da&default-theme=true

RNS Number : 0108D  Trellus Health PLC  17 October 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Two contracts signed with Mount Sinai

IBD self-management solution funded for Mount Sinai Health System employees

and members of large NY state labor union

 

LONDON, U.K. AND NEW YORK, U.S. (17 October 2022). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions which
addresses the intersection of chronic illness with mental health, announces
that it has signed two contracts with the Mount Sinai Health System ("Mount
Sinai") to provide access to the Trellus Resilience Training and
Self-Management Program for Inflammatory Bowel Disease (the "Trellus IBD
program").

 

The first contract will see Mount Sinai make the Trellus IBD program available
to, and paid for, as a wellness benefit, to all Mount Sinai Health System
employees, focusing initially on Inflammatory Bowel Disease ("IBD"), including
Crohn's Disease, and Ulcerative Colitis.Mount Sinai has a robust employee
wellness program which is offered free of charge to all faculty and staff. The
second contract is to make the Trellus IBD program available to eligible
patients, again as a wellness benefit, who are members of a large NY state
labor union, which provides health services and benefits to its members
through Mount Sinai.

 

These contracts support the Company's strategy of accessing patients to expand
the rollout of its solution.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "As
announced in our recent half-year report, Trellus has been making significant
progress in advancing our B2B2C strategy and I am delighted that we have
signed these contracts with such a prestigious partner as Mount Sinai. We
believe that these contracts reflect the importance of our solution to
healthcare providers and employers who want to empower their patients and
employees to master the art of self-management, manage their chronic
conditions with confidence, and improve health outcomes at a significantly
lower cost.

 

"Trellus represents a paradigm shift in the way that we support patients with
chronic health condition incorporating a whole-person methodology that has, to
date, been missing from the collective approach. These contracts with Mount
Sinai will support our commercial goals of adding more patient members to the
Trellus programs through increased access."

 

About the Trellus IBD program

Trellus Health is pioneering a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions which
addresses the intersection of chronic illness with mental health, estimated to
cost the US economy $3.7 trillion annually.(1) Trellus's approach transforms
chronic condition management and changes the lives of patients living with
debilitating, incurable conditions, initially focused on IBD, including
Crohn's Disease and ulcerative colitis, and shortly IBS, but with potential
utility and demand across many chronic conditions.

 

The Trellus IBD program is a self-management solution driven by personalized
resilience training. The program empowers and enables members to manage their
condition by teaching them to set goals, actively identify challenges and
solve problems associated with their condition, driving a change of health
behavior to deliver improved outcomes and health status at lower cost.

 

Patients with IBD face many challenges which are common across many chronic
conditions: the management of complex medication regimens, dealing with
symptoms and disability, monitoring physical indicators, maintaining proper
levels of nutrition, adjusting to the psychological and social demands
including difficult lifestyle adjustments, as well as engaging in effective
interactions with health providers.

 

Trellus's personalized resilience-driven self-management training programs are
designed specifically for people looking to overcome these challenges. The aim
is to provide better quality patient outcomes at a lower cost to health plans
and employers, and the proprietary resilience method has been proven to reduce
unplanned hospitalizations by 94% at the Mount Sinai IBD Center, New York,
NY.(2)

 

The Trellus IBD program described is based on technology developed by Mount
Sinai faculty and licensed to Trellus Health. Mount Sinai and Mount Sinai
faculty, including Marla Dubinsky, MD, and Laurie Keefer, PhD, have a
financial interest in Trellus Health. Mount Sinai has representation on the
Trellus Health Board of Directors.

 

For further information please contact:

 

 Trellus Health plc                                                         https://trellushealth.com/ (https://trellushealth.com/)
 Julian Baines, Non-executive Chairman                                      Via Walbrook PR
 Dr. Marla Dubinsky, Chief Executive Officer
 Steve Young, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)                      Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / 7748 651 727 / 7867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience based digital health
company focused on the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden, building self-management
skills and promoting individual health behaviors that enable thriving in the
face of a chronic condition. Through its TrellusElevate™ connected health
platform and companion App, the company addresses both physical and behavioral
health together, in context, to improve outcomes and reduce healthcare costs
across the healthcare ecosystem.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, and shortly Irritable Bowel Syndrome ("IBS"), but, given the common
struggles of self-management, considers its approach to have potential utility
and demand across many chronic conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. Patients with IBD treated using the methodology
also experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following starting the program(2).

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™
resilience assessment and personalized resilience training methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

 

1) Source: https://www.cdc.gov/chronicdisease/about/costs/index.htm
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.cdc.gov_chronicdisease_about_costs_index.htm&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=fSst1AtlXyuqcs3cHJXcCRilbI1Qm1WfjNYkVgQfiLE&m=IjQVBqsF0mJCc4cCch3kNewShI3X349VlYSUrh3C5-c&s=lilxcTv-hIGGEbeSix8wsDKl8TOyuP3Vw__GebvZFro&e=)
)

2) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBRBDGBGBDGDS